Literature DB >> 9609759

Differential activation of IGF-II promoters P3 and P4 in Caco-2 cells during growth and differentiation.

P Singh1, B Dai, R L Given, X Lu, P E Holthuizen.   

Abstract

BACKGROUND & AIMS: Insulin-like growth factor (IGF)-II gene is overexpressed in colon cancers. Transcriptional up-regulation may be the major mechanism contributing to its overexpression. IGF-II messenger RNA (mRNA) levels are up-regulated during proliferation followed by a significant decline during differentiation of Caco-2 cells. Mechanisms underlying transcriptional regulation of the IGF-II gene promoters (P1-P4) have yet to be examined in colon cancers, which was the basis for this study.
METHODS: Ribonuclease protection assay was used to measure IGF-II mRNA derived from P1-P4. To determine if changes in the IGF-II transcripts reflected differences in promoter activity, transient transfection assays with the full-length P1-P4-luciferase expression vectors were performed.
RESULTS: Both P3- and P4-derived transcripts were significantly up-regulated during the proliferative phase of the cells (days 3-6 in culture) and declined rapidly in cells undergoing differentiation (days 7-10); conversely, P1- and P2-derived transcripts were not detected. Similarly, transcriptional activity of P3 and P4 promoters reached peak levels by days 4-6 and declined rapidly thereafter. P1 and P2 were relatively inactive on all days.
CONCLUSIONS: The activity of the P3 and P4 promoters may play a selective role in regulating IGF-II mRNA levels during growth and differentiation of colon cancer cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9609759     DOI: 10.1016/s0016-5085(98)70428-7

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  7 in total

1.  Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms.

Authors:  C Unger; N Kramer; D Unterleuthner; M Scherzer; A Burian; A Rudisch; M Stadler; M Schlederer; D Lenhardt; A Riedl; S Walter; A Wernitznig; L Kenner; M Hengstschläger; J Schüler; W Sommergruber; H Dolznig
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

2.  Kinetics and regulation of site-specific endonucleolytic cleavage of human IGF-II mRNAs.

Authors:  E L van Dijk; J S Sussenbach; P E Holthuizen
Journal:  Nucleic Acids Res       Date:  2001-09-01       Impact factor: 16.971

3.  WT1 expression is increased in primary fibroblasts derived from Dupuytren's disease tissues.

Authors:  Justin Crawford; Christina Raykha; Daevina Charles; Bing Siang Gan; David B O'Gorman
Journal:  J Cell Commun Signal       Date:  2015-06-30       Impact factor: 5.782

4.  Development of targeted therapy for a broad spectrum of solid tumors mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P4 and IGF2-P3 regulatory sequences.

Authors:  Doron Amit; Sagi Tamir; Abraham Hochberg
Journal:  Int J Clin Exp Med       Date:  2013-01-26

5.  Insulin-like growth factor-II is increased in systemic sclerosis-associated pulmonary fibrosis and contributes to the fibrotic process via Jun N-terminal kinase- and phosphatidylinositol-3 kinase-dependent pathways.

Authors:  Eileen Hsu; Carol A Feghali-Bostwick
Journal:  Am J Pathol       Date:  2008-05-08       Impact factor: 4.307

6.  STAT3-mediated IGF-2 secretion in the tumour microenvironment elicits innate resistance to anti-IGF-1R antibody.

Authors:  Ji-Sun Lee; Ju-Hee Kang; Hye-Jin Boo; Su-Jung Hwang; Sungyoul Hong; Su-Chan Lee; Young-Jun Park; Tae-Moon Chung; Hyewon Youn; Seung Mi Lee; Byoung Jae Kim; June-Key Chung; Yeonseok Chung; William N William; Young Kee Shin; Hyo-Jong Lee; Seung-Hyun Oh; Ho-Young Lee
Journal:  Nat Commun       Date:  2015-10-14       Impact factor: 14.919

7.  Essential role of insulin-like growth factor 2 in resistance to histone deacetylase inhibitors.

Authors:  S-C Lee; H-Y Min; H J Jung; K H Park; S Y Hyun; J Cho; J K Woo; S J Kwon; H-J Lee; F M Johnson; H-Y Lee
Journal:  Oncogene       Date:  2016-04-18       Impact factor: 9.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.